Tech Company Financing Transactions
Amolyt Pharma Funding Round
Amolyt Pharma, based in Ecully, secured $138 million from Intermediate Capital Group, Sofinnova Partners and Andera Partners.
Transaction Overview
Company Name
Announced On
1/9/2023
Transaction Type
Venture Equity
Amount
$138,000,000
Round
Series C
Investors
Intermediate Capital Group (Lead Investor)
Sofinnova Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
15, chemin du Saquin Espace Européen, Building G
Ecully, 69 130
FR
Ecully, 69 130
FR
Phone
Website
Email Address
Overview
We are building and advancing a portfolio through global approval by establishing strong ties and collaborations with endocrinologists, the medical community at large and patient advocacy organizations worldwide.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thierry Abribat
Chief Financial Officer
Louis Arcudi
Chief Medical Officer
Mark Sumeray
Chief Scientific Officer
Michael Culler
Browse more venture capital transactions:
Prev: 1/9/2023: Monogram Health venture capital transaction
Next: 1/9/2023: ToxStrategies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs